Can I take suvotinib after becoming resistant to Mobocertinib?

Mobocertinib (Mobocertinib) is a tyrosine kinase inhibitor used to treat epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer. If a patient develops resistance to mobosetinib, savolitinib may be an optional treatment option. Suvotinib, a MET receptor kinase inhibitor, was recently approved in China based on the results of a pivotal Phase II trial in patients with non-small cell lung cancer/pulmonary sarcomatoid carcinoma (Conditional on the results of the Phase III trial). For the treatment of metastatic non-small cell lung cancer with MET exon 14 skipping alterations in patients who have progressed after platinum-based chemotherapy or who are intolerant to platinum-based chemotherapy However, the specific treatment plan should be determined by the doctor based on the patient's specific situation.